News

A Phase 2 trial evaluating the efficacy and safety of investigational Anavex 2-73 as a treatment for Parkinson’s disease dementia has recruited half of its targeted patients, the therapy’s developer, Anavex Life Sciences, has announced. The study is still recruiting Parkinson’s disease patients age 50 or older who have been diagnosed with…

Parkinson’s patients who have had the disease for a long time, who do not sleep very efficiently, and have higher motor impairment are more likely to experience sleep benefit — the phenomenon in which Parkinson’s patients wake up feeling better before taking medication. The study with that finding, “…

Seelos Therapeutics has acquired an exclusive license to further develop a treatment approach called SLS-007 for Parkinson’s disease which is intended to lessen the aggregation of alpha-synuclein protein. The therapeutic strategy was developed by scientists at University of California, Los Angeles, and includes a family of peptide blockers that…

In contrast to what was previously believed, a key protein implicated in Parkinson’s disease — called Nurr1 — can be modulated using naturally existing molecules or engineered small molecules to restore dopamine production in brain cells, according to a study. Conducted by researchers from the University of California San…

Researchers in Australia are planning to test therapies already being used in other inflammatory conditions, as well as new compounds, for their potential to block brain inflammation and halt Parkinson’s disease progression. Conducted by researchers at The University of Queensland (UQ) in Australia, the study, “Pharmacological…

To further support its quest to advance a new therapy for Parkinson’s disease and related disorders, Inhibikase Therapeutics has added three leading researchers to its Scientific Advisory Board (SAB). The pharmaceutical company is developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases. Its pipeline…

The National Institutes of Health (NIH) has granted a Michigan State University scientist $5 million to study a possible link between pesticides, a diminished sense of smell, and early symptoms of diseases such as Parkinson’s among older farmers. The investigator is Honglei Chen, MD, PhD, a professor of…

Antiparkinsonian medicines may allow patients with mild to moderate Parkinson’s disease to experience freedom of movement, which could be confused with balance issues if measured by traditional postural stability testing, researchers suggest. Their findings were published in the study, “The influence of dopaminergic medication on…

New preclinical data have shown for the first time the underlying mechanisms mediating the therapeutic activity of Anavex 2-73, an investigational therapy being evaluated for the treatment of neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). Anavex Life Sciences’ investigational activator of the sigma-1 receptor…

A protein called osteonectin may be implicated in Parkinson’s and other neurodegenerative diseases, according to a computer-based analysis. The study, “In silico method for identification of novel copper and iron metabolism proteins in various neurodegenerative disorders,” was published  in the journal NeuroToxicology. Excessive production of copper and…